Inflammatory biomarkers CRP, MCP-1, serum amyloid alpha and interleukin-18 in patients with HTN and dyslipidemia: impact of diabetes mellitus on metabolic syndrome and the effect of statin therapy (Q42686418)

From Wikidata

Jump to navigation Jump to search

scientific article published on 7 February 2013

Language	Label	Description	Also known as
English	Inflammatory biomarkers CRP, MCP-1, serum amyloid alpha and interleukin-18 in patients with HTN and dyslipidemia: impact of diabetes mellitus on metabolic syndrome and the effect of statin therapy	scientific article published on 7 February 2013

Statements

scholarly article

1 reference

Europe PubMed Central

4 November 2017

Inflammatory biomarkers CRP, MCP-1, serum amyloid alpha and interleukin-18 in patients with HTN and dyslipidemia: impact of diabetes mellitus on metabolic syndrome and the effect of statin therapy (English)

1 reference

Europe PubMed Central

4 November 2017

0 references

1 reference

based on heuristic

inferred from title

metabolic syndrome

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Simon W Rabkin

1

1 reference

Europe PubMed Central

4 November 2017

Anatoly Langer

2

1 reference

Europe PubMed Central

4 November 2017

Ehud Ur

3

1 reference

Europe PubMed Central

4 November 2017

Cristina-Dana Calciu

4

1 reference

Europe PubMed Central

4 November 2017

Lawrence A Leiter

5

1 reference

Europe PubMed Central

4 November 2017

publication date

7 February 2013

1 reference

Europe PubMed Central

4 November 2017

Hypertension Research

1 reference

Europe PubMed Central

4 November 2017

36

1 reference

Europe PubMed Central

4 November 2017

6

1 reference

Europe PubMed Central

4 November 2017

550-558

1 reference

Europe PubMed Central

4 November 2017

https://scigraph.springernature.com/pub.10.1038/hr.2012.214

0 references

Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Inflammation, obesity, and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Associations between inflammatory markers, traditional risk factors, and complications in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

The relationship between inflammation, obesity and risk for hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA).

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Inflammation in atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Implications of early structural-functional changes in the endothelium for vascular disease

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Serum amyloid A: the "other" inflammatory protein

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE).

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Differential effect of LFA703, pravastatin, and fluvastatin on production of IL-18 and expression of ICAM-1 and CD40 in human monocytes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Effects of fluvastatin therapy on serum interleukin-18 and interleukin-10 levels in patients with acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titrati

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratifie

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

American Heart Association Guide for Improving Cardiovascular Health at the Community Level

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

C-reactive protein in hypertension: clinical significance and predictive value

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Elevated high-sensitive C-reactive protein, large arterial stiffness and atherosclerosis: a relationship between inflammation and hypertension?

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME).

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Monocyte chemoattractant protein-1 and CC-chemokine receptor-2 in severe hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Monocyte chemoattractant protein-1: a key mediator of angiotensin II-induced target organ damage in hypertensive heart disease?

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Relation of left ventricular concentric remodeling to levels of C-reactive protein and serum amyloid A in patients with essential hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Long-term effects of statins on arterial pressure and stiffness of hypertensives

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Inflammation and Carotid Artery—Risk for Atherosclerosis Study (ICARAS)

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Serum amyloid A is present in the capillaries and microinfarcts of hypertensive monkey brain: An immunohistochemical study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Chemokines and atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

21 January 2018

Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammatory response and re-stenosis after percutaneous coronary intervention in heart transplant recipients and patients with native atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

7 January 2021

based on heuristic

inferred from DOI database lookup

Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

7 January 2021

based on heuristic

inferred from DOI database lookup

Simvastatin exerts its anti-inflammatory effect in hypercholesterolaemic patients by decreasing the serum levels of monocyte chemoattractant protein-1

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between low-grade inflammation and arterial stiffness in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

7 January 2021

based on heuristic

inferred from DOI database lookup

Alpha-1 microglobulin as a new inflammatory marker in newly diagnosed hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.214

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/HR.2012.214

1 reference

Europe PubMed Central

4 November 2017

1 reference

Europe PubMed Central

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42686418&oldid=1965559456"